| 1.25 0.02 (1.63%) | 12-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.56 | 1-year : | 1.76 |
| Resists | First : | 1.34 | Second : | 1.5 |
| Pivot price | 1.26 |
|||
| Supports | First : | 1.07 | Second : | 0.89 |
| MAs | MA(5) : | 1.33 | MA(20) : | 1.25 |
| MA(100) : | 1.22 |
MA(250) : | 1.47 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 55.3 |
D(3) : | 72.5 |
| RSI | RSI(14): 49.6 |
|||
| 52-week | High : | 2.06 | Low : | 0.89 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ OPTN ] has closed above bottom band by 45.4%. Bollinger Bands are 51.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.25 - 1.26 | 1.26 - 1.26 |
| Low: | 1.16 - 1.16 | 1.16 - 1.17 |
| Close: | 1.24 - 1.25 | 1.25 - 1.26 |
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Wed, 06 Dec 2023
Healthcare Stocks on the Move Wednesday: SERA, PHIO, SYRS, ALT, IPA, RDHL, OPTN, CCCC - InvestorsObserver
Wed, 06 Dec 2023
How Will the Market React to OptiNose Inc (OPTN) Stock Getting a Bullish Rating - InvestorsObserver
Wed, 06 Dec 2023
Why ENT-Focused OptiNose (OPTN) Shares Are Diving Today - OptiNose (NASDAQ:OPTN) - Benzinga
Wed, 06 Dec 2023
Optinose stock falls on delay for Xhance label expansion - Seeking Alpha
Tue, 05 Dec 2023
OptiNose, Inc. (NASDAQ:OPTN) institutional owners may be pleased with recent gains after 16% loss over the past year - Simply Wall St
Thu, 09 Nov 2023
OptiNose: Q3 Earnings Snapshot - Houston Chronicle
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers—Specialty & Generic
|
|
| Shares Out | 112 (M) |
| Shares Float | 68 (M) |
| Held by Insiders | 7.4 (%) |
| Held by Institutions | 78.4 (%) |
| Shares Short | 3,740 (K) |
| Shares Short P.Month | 3,770 (K) |
| EPS | -0.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.69 |
| Profit Margin | -56.5 % |
| Operating Margin | -8.6 % |
| Return on Assets (ttm) | -17.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -1.3 % |
| Gross Profit (p.s.) | 0.59 |
| Sales Per Share | 0.64 |
| EBITDA (p.s.) | -0.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -3.29 |
| PEG Ratio | -0.1 |
| Price to Book value | -1.82 |
| Price to Sales | 1.95 |
| Price to Cash Flow | -3.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|